MapLight Therapeutics (MPLT) Long-Term Investments (2024 - 2025)
MapLight Therapeutics (MPLT) reported Long-Term Investments of $148.0 million for Q4 2025, up 1200.47% on a YoY basis from $11.4 million in Q4 2024, and up 1200.47% sequentially from $11.4 million in Q4 2024.
MapLight Therapeutics (MPLT) Long-Term Investments (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Long-Term Investments data on file, last reported at $148.0 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Investments rose 1200.47% year-over-year to $148.0 million; the trailing twelve-month figure through Dec 2025 stood at $148.0 million (up 1200.47% YoY), and the FY2025 full-year result was $148.0 million, up 1200.47% from the prior year.
- Long-Term Investments improved to $148.0 million in Q4 2025, from $11.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $148.0 million in Q4 2025 to a low of $11.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 147.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147.99 Mn |
| Dec 31, 2024 | 11.38 Mn |